<p>泰瓦制药工业有限公司（NYSE:TEVA - 获取免费报告）在周一创下了 52 周的新高，此前 Piper Sandler 将其股票目标价从 30.00 美元上调至 40.00 美元。Piper Sandler 目前对该股票给予超配评级。泰瓦制药的股价最高达到 30.98 美元，最后交易价为 30.9730 美元，成交量为 1205448 股。该股票此前收盘价为 30.35 美元。</p>
<ul>
<li>MarketBeat 周回顾 – 02/03 - 02/07</li>
</ul>
<p>TEVA 已成为多份研究报告的主题。高盛集团在周五的研究报告中将泰瓦制药的目标价从 31.00 美元上调至 35.00 美元，并给予该公司 “买入” 评级。瑞银集团在 9 月 24 日的研究报告中将泰瓦制药的目标价从 23.00 美元上调至 26.00 美元，并给予该公司 “买入” 评级。巴克莱在 12 月 9 日的研究报告中开始覆盖泰瓦制药的股票，给予 “超配” 评级和 35.00 美元的目标价。摩根大通在 12 月 16 日的研究报告中将泰瓦制药的目标价从 28.00 美元上调至 35.00 美元，并给予该公司 “超配” 评级。最后，Weiss Ratings 在 10 月 8 日的报告中重申了对泰瓦制药的 “卖出（d-）” 评级。三位股票研究分析师给予该股票强烈买入评级，六位给予买入评级，一位给予卖出评级。根据 MarketBeat.com，该公司目前的共识评级为 “买入”，共识目标价为 32.88 美元。</p>
<p><strong>查看我们关于 TEVA 的最新报告</strong></p>
<h2>内部活动</h2>
<ul>
<li>泰瓦制药：为什么这家仿制药巨头现在是一个明智的投资</li>
</ul>
<p>在其他泰瓦制药的新闻中，副总裁 Richard Daniell 在 12 月 9 日的交易中出售了 115,468 股公司的股票。该股票以 28.68 美元的平均价格出售，总价值为 3,311,622.24 美元。交易完成后，该副总裁持有 48,384 股公司的股票，价值约为 1,387,653.12 美元。这一交易使其持股减少了 70.47%。该出售在向证券交易委员会的备案中披露，相关信息可以通过此链接访问。此外，首席会计官 Amir Weiss 在 12 月 16 日的交易中出售了 12,300 股泰瓦制药的股票。该股票以 30.20 美元的平均价格出售，总交易额为 371,460.00 美元。交易完成后，首席会计官持有 5,650 股公司的股票，价值为 170,630 美元。这代表其持股减少了 68.52%。该出售的 SEC 备案提供了更多信息。在过去三个月中，内部人士出售了 622,060 股公司股票，价值 17,076,965 美元。当前内部人士持有 0.55% 的股票。</p>
<h2>机构投资者对泰瓦制药的看法</h2>
<p>一些对冲基金最近调整了对 TEVA 的持股。Advisors Asset Management Inc.在第二季度购买了泰瓦制药的股票，价值 41,000 美元。Cromwell Holdings LLC 在第三季度将其在泰瓦制药的持股增加了 40.3%。Cromwell Holdings LLC 现在拥有 2,191 股公司的股票，价值 44,000 美元，此前在上个季度购买了 629 股。Sound Income Strategies LLC 在第二季度将其在泰瓦制药的持股增加了 3,715.8%。Sound Income Strategies LLC 现在拥有 2,900 股公司的股票，价值 49,000 美元，此前在上个季度购买了 2,824 股。MAI Capital Management 在第二季度将其在泰瓦制药的持股增加了 26.8%。MAI Capital Management 现在拥有 3,293 股公司的股票，价值 55,000 美元，此前在上个季度购买了 697 股。最后，Rothschild Investment LLC 在第三季度将其在泰瓦制药的持股增加了 97.0%。Rothschild Investment LLC 现在拥有 2,738 股公司的股票，价值 55,000 美元，此前在上个季度购买了 1,348 股。机构投资者持有该公司 54.05% 的股票。</p>
<h2>泰瓦制药股票表现</h2>
<ul>
<li>2 只准备在 2025 年飙升的仿制药股票</li>
</ul>
<p>该公司的 50 日移动平均线为 24.44 美元，200 日移动平均线为 20.08 美元。公司的市值为 355.5 亿美元，市盈率为 51.62，市盈增长比率为 1.81，贝塔值为 0.67。该公司的速动比率为 0.82，流动比率为 1.11，债务股本比率为 2.31。</p>
<h2>关于泰瓦制药工业</h2>
<p>（获取免费报告）</p>
<p>泰瓦制药工业有限公司 NYSE: TEVA 是一家以色列跨国制药公司，也是全球最大的仿制药制造商之一。公司的核心业务包括仿制药的开发、生产和营销，以及一系列专利品牌药物的组合。泰瓦向全球市场提供成品剂型和活性药物成分（APIs），并在多个国家运营制造和研究设施。</p>
<p>泰瓦的产品范围涵盖口服固体剂型、注射剂、吸入产品及其他剂型，涉及中枢神经系统疾病、呼吸系统、肿瘤、疼痛和传染病等治疗领域。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票超过泰瓦制药</li>
<li>华尔街股票挑选者评选 2026 年第一只股票</li>
<li>请勿删除，立即阅读</li>
<li>100 万美元在退休后能维持多久？</li>
<li>在 2026 年 1 月 1 日之前购买这只 2 美元的黄金股票</li>
<li>“客户银行存款面临 6.6 万亿美元的风险”</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在梯瓦制药吗？</h2>
<p>在考虑梯瓦制药之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而梯瓦制药并不在名单上。</p>
<p>虽然梯瓦制药目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

梯瓦制药

<p>梯瓦制药 (NYSE:TEVA) 在皮博格·桑德勒将其目标价从 30.00 美元上调至 40.00 美元并维持增持评级后，达到了新的 52 周高点。其他分析师，包括高盛和瑞银，也上调了他们的目标价。内部交易活动显示公司高管进行了大量股票出售。机构投资者增加了他们的持股。该公司的市值为 355.5 亿美元，市盈率为 51.62</p>

<p>Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) reached a new 52-week high on Monday after Piper Sandler raised their price target on the stock from $30.00 to $40.00. Piper Sandler currently has an overweight rating on the stock. Teva Pharmaceutical Industries traded as high as $30.98 and last traded at $30.9730, with a volume of 1205448 shares trading hands. The stock had previously closed at $30.35.</p>
<div class="lb-trans"><p>泰瓦制药工业有限公司（NYSE:TEVA - 获取免费报告）在周一创下了 52 周的新高，此前 Piper Sandler 将其股票目标价从 30.00 美元上调至 40.00 美元。Piper Sandler 目前对该股票给予超配评级。泰瓦制药的股价最高达到 30.98 美元，最后交易价为 30.9730 美元，成交量为 1205448 股。该股票此前收盘价为 30.35 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 02/03 - 02/07</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 02/03 - 02/07</li>
</ul>
</div><p>TEVA has been the subject of a number of other research reports. The Goldman Sachs Group raised their target price on Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the company a &#34;buy&#34; rating in a research note on Friday. UBS Group raised their price objective on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, September 24th. Barclays began coverage on shares of Teva Pharmaceutical Industries in a research report on Tuesday, December 9th. They issued an &#34;overweight&#34; rating and a $35.00 target price on the stock. JPMorgan Chase &amp; Co. lifted their price target on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an &#34;overweight&#34; rating in a research report on Tuesday, December 16th. Finally, Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of &#34;Buy&#34; and a consensus price target of $32.88.</p>
<div class="lb-trans"><p>TEVA 已成为多份研究报告的主题。高盛集团在周五的研究报告中将泰瓦制药的目标价从 31.00 美元上调至 35.00 美元，并给予该公司 “买入” 评级。瑞银集团在 9 月 24 日的研究报告中将泰瓦制药的目标价从 23.00 美元上调至 26.00 美元，并给予该公司 “买入” 评级。巴克莱在 12 月 9 日的研究报告中开始覆盖泰瓦制药的股票，给予 “超配” 评级和 35.00 美元的目标价。摩根大通在 12 月 16 日的研究报告中将泰瓦制药的目标价从 28.00 美元上调至 35.00 美元，并给予该公司 “超配” 评级。最后，Weiss Ratings 在 10 月 8 日的报告中重申了对泰瓦制药的 “卖出（d-）” 评级。三位股票研究分析师给予该股票强烈买入评级，六位给予买入评级，一位给予卖出评级。根据 MarketBeat.com，该公司目前的共识评级为 “买入”，共识目标价为 32.88 美元。</p>
</div><p><strong>View Our Latest Report on TEVA</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 TEVA 的最新报告</strong></p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><ul>
<li>Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now</li>
</ul>
<div class="lb-trans"><ul>
<li>泰瓦制药：为什么这家仿制药巨头现在是一个明智的投资</li>
</ul>
</div><p>In other Teva Pharmaceutical Industries news, VP Richard Daniell sold 115,468 shares of the business's stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $28.68, for a total value of $3,311,622.24. Following the completion of the transaction, the vice president owned 48,384 shares of the company's stock, valued at approximately $1,387,653.12. The trade was a 70.47% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, CAO Amir Weiss sold 12,300 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $30.20, for a total transaction of $371,460.00. Following the completion of the sale, the chief accounting officer owned 5,650 shares of the company's stock, valued at $170,630. This represents a 68.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 622,060 shares of company stock worth $17,076,965 over the last three months. 0.55% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他泰瓦制药的新闻中，副总裁 Richard Daniell 在 12 月 9 日的交易中出售了 115,468 股公司的股票。该股票以 28.68 美元的平均价格出售，总价值为 3,311,622.24 美元。交易完成后，该副总裁持有 48,384 股公司的股票，价值约为 1,387,653.12 美元。这一交易使其持股减少了 70.47%。该出售在向证券交易委员会的备案中披露，相关信息可以通过此链接访问。此外，首席会计官 Amir Weiss 在 12 月 16 日的交易中出售了 12,300 股泰瓦制药的股票。该股票以 30.20 美元的平均价格出售，总交易额为 371,460.00 美元。交易完成后，首席会计官持有 5,650 股公司的股票，价值为 170,630 美元。这代表其持股减少了 68.52%。该出售的 SEC 备案提供了更多信息。在过去三个月中，内部人士出售了 622,060 股公司股票，价值 17,076,965 美元。当前内部人士持有 0.55% 的股票。</p>
</div><h2>Institutional Investors Weigh In On Teva Pharmaceutical Industries</h2>
<div class="lb-trans"><h2>机构投资者对泰瓦制药的看法</h2>
</div><p>A number of hedge funds have recently modified their holdings of TEVA. Advisors Asset Management Inc. purchased a new position in shares of Teva Pharmaceutical Industries in the second quarter worth $41,000. Cromwell Holdings LLC grew its position in shares of Teva Pharmaceutical Industries by 40.3% during the third quarter. Cromwell Holdings LLC now owns 2,191 shares of the company's stock valued at $44,000 after purchasing an additional 629 shares in the last quarter. Sound Income Strategies LLC increased its holdings in shares of Teva Pharmaceutical Industries by 3,715.8% in the second quarter. Sound Income Strategies LLC now owns 2,900 shares of the company's stock worth $49,000 after purchasing an additional 2,824 shares during the last quarter. MAI Capital Management increased its holdings in shares of Teva Pharmaceutical Industries by 26.8% in the second quarter. MAI Capital Management now owns 3,293 shares of the company's stock worth $55,000 after purchasing an additional 697 shares during the last quarter. Finally, Rothschild Investment LLC lifted its position in shares of Teva Pharmaceutical Industries by 97.0% in the third quarter. Rothschild Investment LLC now owns 2,738 shares of the company's stock worth $55,000 after buying an additional 1,348 shares in the last quarter. Institutional investors own 54.05% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金最近调整了对 TEVA 的持股。Advisors Asset Management Inc.在第二季度购买了泰瓦制药的股票，价值 41,000 美元。Cromwell Holdings LLC 在第三季度将其在泰瓦制药的持股增加了 40.3%。Cromwell Holdings LLC 现在拥有 2,191 股公司的股票，价值 44,000 美元，此前在上个季度购买了 629 股。Sound Income Strategies LLC 在第二季度将其在泰瓦制药的持股增加了 3,715.8%。Sound Income Strategies LLC 现在拥有 2,900 股公司的股票，价值 49,000 美元，此前在上个季度购买了 2,824 股。MAI Capital Management 在第二季度将其在泰瓦制药的持股增加了 26.8%。MAI Capital Management 现在拥有 3,293 股公司的股票，价值 55,000 美元，此前在上个季度购买了 697 股。最后，Rothschild Investment LLC 在第三季度将其在泰瓦制药的持股增加了 97.0%。Rothschild Investment LLC 现在拥有 2,738 股公司的股票，价值 55,000 美元，此前在上个季度购买了 1,348 股。机构投资者持有该公司 54.05% 的股票。</p>
</div><h2>Teva Pharmaceutical Industries Stock Performance</h2>
<div class="lb-trans"><h2>泰瓦制药股票表现</h2>
</div><ul>
<li>2 Generic Drug Stocks Ready to Surge in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只准备在 2025 年飙升的仿制药股票</li>
</ul>
</div><p>The business has a 50 day moving average of $24.44 and a 200 day moving average of $20.08. The company has a market capitalization of $35.55 billion, a P/E ratio of 51.62, a price-to-earnings-growth ratio of 1.81 and a beta of 0.67. The company has a quick ratio of 0.82, a current ratio of 1.11 and a debt-to-equity ratio of 2.31.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均线为 24.44 美元，200 日移动平均线为 20.08 美元。公司的市值为 355.5 亿美元，市盈率为 51.62，市盈增长比率为 1.81，贝塔值为 0.67。该公司的速动比率为 0.82，流动比率为 1.11，债务股本比率为 2.31。</p>
</div><h2>About Teva Pharmaceutical Industries</h2>
<div class="lb-trans"><h2>关于泰瓦制药工业</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.</p>
<div class="lb-trans"><p>泰瓦制药工业有限公司 NYSE: TEVA 是一家以色列跨国制药公司，也是全球最大的仿制药制造商之一。公司的核心业务包括仿制药的开发、生产和营销，以及一系列专利品牌药物的组合。泰瓦向全球市场提供成品剂型和活性药物成分（APIs），并在多个国家运营制造和研究设施。</p>
</div><p>Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.</p>
<div class="lb-trans"><p>泰瓦的产品范围涵盖口服固体剂型、注射剂、吸入产品及其他剂型，涉及中枢神经系统疾病、呼吸系统、肿瘤、疼痛和传染病等治疗领域。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Teva Pharmaceutical Industries</li>
<li>Wall Street Stock picker Names #1 Stock of 2026</li>
<li>Do not delete, read immediately</li>
<li>How Long Will $1M Last in Retirement?</li>
<li>Buy this $2 Gold Stock Before January 1, 2026</li>
<li>“$6.6 Trillion Of Customer Bank Deposits At Risk”</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过泰瓦制药</li>
<li>华尔街股票挑选者评选 2026 年第一只股票</li>
<li>请勿删除，立即阅读</li>
<li>100 万美元在退休后能维持多久？</li>
<li>在 2026 年 1 月 1 日之前购买这只 2 美元的黄金股票</li>
<li>“客户银行存款面临 6.6 万亿美元的风险”</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Teva Pharmaceutical Industries Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在梯瓦制药吗？</h2>
</div><p>Before you consider Teva Pharmaceutical Industries, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑梯瓦制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而梯瓦制药并不在名单上。</p>
</div><p>While Teva Pharmaceutical Industries currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然梯瓦制药目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

梯瓦制药（NYSE:TEVA）因分析师上调评级而创下 1 年新高